Patents Assigned to Novavax, Inc.
-
Patent number: 11938179Abstract: Disclosed herein are methods and compositions for treating or preventing bacterial infection. In particular, the methods and compositions are directed towards C. difficile infection. In particular aspects, the compositions are vaccines containing multimeric polypeptides containing portions of multiple toxins from bacteria. The polypeptides induce effective immune responses thus treating or preventing infection.Type: GrantFiled: August 10, 2021Date of Patent: March 26, 2024Assignee: Novavax, Inc.Inventors: Jing-Hui Tian, Ye Liu, Gale Smith, Gregory Glenn, David Flyer
-
Patent number: 11896664Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.Type: GrantFiled: January 10, 2022Date of Patent: February 13, 2024Assignee: Novavax, Inc.Inventors: Gale Smith, Michael J. Massare, Jing-Hui Tian
-
Patent number: 11896662Abstract: Disclosed herein are multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines. The nanoparticles include effective amounts of influenza glycoproteins that provide increased immune responses compared to a commercially available influenza vaccine composition. The present disclosure also provides vaccine formulation strategies that are cost effective and are convenient for clinical use. Methods of administering the nanoparticle vaccine compositions to a subject are also disclosed.Type: GrantFiled: November 24, 2021Date of Patent: February 13, 2024Assignee: Novavax, Inc.Inventors: Sarathi Boddapati, Anushree Herwadkar, Jason Wong, Yen-Huei Lin, Gale Smith, Jing-Hui Tian
-
Patent number: 11541112Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.Type: GrantFiled: February 8, 2021Date of Patent: January 3, 2023Assignee: Novavax, Inc.Inventors: Gale Smith, Michael J. Massare, Jing-Hui Tian
-
Patent number: 11446374Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.Type: GrantFiled: October 11, 2019Date of Patent: September 20, 2022Assignee: Novavax, Inc.Inventors: Peter M. Pushko, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou
-
Patent number: 11364294Abstract: Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.Type: GrantFiled: November 21, 2017Date of Patent: June 21, 2022Assignee: Novavax, Inc.Inventors: Gale Smith, Ye Liu, Jing-Hui Tian, Michael J. Massare, Sarathi Boddapati, Erica Shane, Cynthia Oliver, Gregory Glenn
-
Patent number: 11278612Abstract: Disclosed herein are multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines. The nanoparticles include effective amounts of influenza glycoproteins that provide increased immune responses compared to a commercially available influenza vaccine composition. The present disclosure also provides vaccine formulation strategies that are cost effective and are convenient for clinical use. Methods of administering the nanoparticle vaccine compositions to a subject are also disclosed.Type: GrantFiled: March 19, 2019Date of Patent: March 22, 2022Assignee: Novavax, Inc.Inventors: Sarathi Boddapati, Anushree Herwadkar, Jason Wong, Yen-Huei Lin, Gale Smith, Jing-Hui Tian
-
Patent number: 11253586Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.Type: GrantFiled: March 18, 2021Date of Patent: February 22, 2022Assignee: Novavax, Inc.Inventors: Gale Smith, Michael J. Massare, Jing-Hui Tian
-
Patent number: 11253585Abstract: Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.Type: GrantFiled: August 20, 2019Date of Patent: February 22, 2022Assignee: Novavax, Inc.Inventors: Gale Smith, Ye Liu, Jing-Hui Tian, Michael J. Massare, Sarathi Boddapati, Erica Shane, Cynthia Oliver, Gregory Glenn
-
Patent number: 11123419Abstract: Disclosed herein are methods and compositions for treating or preventing bacterial infection. In particular, the methods and compositions are directed towards C. difficile infection. In particular aspects, the compositions are vaccines containing multimeric polypeptides containing portions of multiple toxins from bacteria. The polypeptides induce effective immune responses thus treating or preventing infection.Type: GrantFiled: March 15, 2018Date of Patent: September 21, 2021Assignee: Novavax, Inc.Inventors: Jing-Hui Tian, Ye Liu, Gale Smith, Gregory Glenn, David Flyer
-
Patent number: 11052146Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.Type: GrantFiled: June 15, 2018Date of Patent: July 6, 2021Assignee: Novavax, Inc.Inventors: Peter M. Pushko, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou
-
Patent number: 10953089Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.Type: GrantFiled: August 19, 2020Date of Patent: March 23, 2021Assignee: NOVAVAX, INC.Inventors: Gale Smith, Michael J. Massare, Jing-Hui Tian
-
Patent number: 10751410Abstract: Disclosed herein are nanoparticles containing MERS virus proteins in polymer structures, and compositions containing the nanoparticles formulated for administration as immunogenic compositions. Also provided herein are vector constructs encoding the proteins, and host cells containing the vector constructs. The disclosure also includes methods of making the nanoparticles and administering them to vertebrates, including methods of inducing immune responses to MERS that reduce or prevent infection by the virus.Type: GrantFiled: September 19, 2014Date of Patent: August 25, 2020Assignee: Novavax, Inc.Inventors: Gale Smith, Ye Liu, Michael Massare
-
Patent number: 10729760Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.Type: GrantFiled: December 5, 2018Date of Patent: August 4, 2020Assignee: Novavax, Inc.Inventors: Gale Smith, Rick Bright, Peter M. Pushko, Jinyou Zhang, Kutub Mahmood
-
Patent number: 10548968Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.Type: GrantFiled: February 21, 2018Date of Patent: February 4, 2020Assignee: Novavax, Inc.Inventors: Gale Smith, Rick Bright, Peter M. Pushko, Jinyou Zhang, Kutub Mahmood
-
Patent number: 10544399Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.Type: GrantFiled: March 22, 2018Date of Patent: January 28, 2020Assignee: Novavax, Inc.Inventors: Gale Smith, Yingyun Wu, Michael J. Massare, Peter M. Pushko, Margaret Nathan, Thomas Kort, Robin Robinson
-
Patent number: 10426829Abstract: Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.Type: GrantFiled: September 6, 2016Date of Patent: October 1, 2019Assignee: Novavax, Inc.Inventors: Gale Smith, Ye Liu, Jing-Hui Tian, Michael J. Massare, Sarathi Boddapati, Erica Shane, Cynthia Oliver, Gregory Glenn
-
Patent number: 10188723Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.Type: GrantFiled: May 30, 2017Date of Patent: January 29, 2019Assignee: NOVAVAX, INC.Inventors: Gale Smith, Rick Bright, Peter M. Pushko, Jinyou Zhang, Kutub Mahmood
-
Patent number: 10086065Abstract: The present invention is generally related to virus-like particles (VLPs) comprising rabies virus (RV) glycoproteins (G proteins) and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of rabies virus infection.Type: GrantFiled: June 30, 2017Date of Patent: October 2, 2018Assignee: Novavax, Inc.Inventors: Gale Smith, Ye Liu
-
Patent number: 10022437Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.Type: GrantFiled: August 28, 2015Date of Patent: July 17, 2018Assignee: NOVAVAX, INC.Inventors: Peter Pushko, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou